Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (질병관리청 국립보건연구원 중증열성혈소판감소증후군(SFTS) 치료용 항체 비임상 시료 생산체계 고도화 및 평가과제 협상대상자 선정 )
Regulatory Filings Classification · 90% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ disclosure announcing a material contract award and related details. It is an official regulatory announcement to the stock exchange of a major business event, not an AGM presentation, financial report, management change, share transaction, or other specific category. It therefore falls under the fallback category of General Regulatory Filings (RNS).
2026-05-27 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) for the 17th fiscal period covering 2026.01.01–2026.03.31, submitted to the Financial Services Commission and Korea Exchange. It contains detailed company information, business overview, capital changes, share data, and other comprehensive financial and operational disclosures typical of an interim/quarterly report. This is not merely an announcement of a report but the full quarterly filing itself. Q1 2026
2026-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 85% confidence The document is a Korean ‘임원ㆍ주요주주 특정증권등 소유상황보고서’ (Form 6.1) detailing changes in share ownership by an officer (오한규) of Pangen. It reports purchases/sales of company stock by an insider and is submitted to the securities regulator and exchange. This matches our definition for Director’s Dealing (report of personal share transactions by company directors and executives).
2026-04-24 Korean
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) which is the Korean equivalent of an Annual Report (10-K). It contains detailed company information, financial data, management discussion, and governance details for the fiscal year 2025. Although it is labeled as a 'Correction Report' (정정신고), it is a full-scale annual filing that includes the complete business report content, not just a brief announcement. Therefore, it is classified as an Annual Report (10-K). FY 2025
2026-04-22 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 85% confidence The document is a corporate disclosure detailing the company’s pre‐maturity acquisition of its own issued convertible bonds (including overseas convertible bonds). It provides specifics on bond issuance dates, amounts, repurchase reasons, funding sources, and repayment treatment. This is a financing/capital structure update rather than an earnings release, board change, or report announcement. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-04-20 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 90% confidence The document is a formal notice filed with the Financial Supervisory Service / Korea Exchange regarding the appointment (and potential dismissal/resignation) of an outside director (“사외이사” in Korean). It details the change date, number of directors before/after, and includes biographical and appointment information for the newly appointed outside director. This clearly falls under Board/Management Information (announcement of changes in the company’s board of directors).
2026-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.